scholarly journals Combination Therapy with the Advanced Glycation End Product Cross-Link Breaker, Alagebrium, and Angiotensin Converting Enzyme Inhibitors in Diabetes: Synergy or Redundancy?

Endocrinology ◽  
2007 ◽  
Vol 148 (2) ◽  
pp. 886-895 ◽  
Author(s):  
Melinda T. Coughlan ◽  
Vicki Thallas-Bonke ◽  
Josefa Pete ◽  
David M. Long ◽  
Anna Gasser ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Angiotensin Converting Enzyme ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Cross Link ◽  
Advanced Glycation ◽  
Converting Enzyme Inhibitors ◽  
Advanced Glycation End Product

scholarly journals AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR AND CALCIUM ANTAGONIST COMBINATION IN PHARMACOTHERAPY OF ARTERIAL HYPERTENSION

2014 ◽  
Vol 13 (1) ◽  
pp. 64-68
Author(s):  
L. L. Kirichenko ◽  
S. V. Gatsura ◽  
A. N. Golosova ◽  
K. V. Ovsyannikov ◽  
O. V. Budik ◽  
...  
Keyword(s):  
Calcium Antagonist ◽  
Endothelial Dysfunction ◽  
Combination Therapy ◽  
Angiotensin Converting Enzyme ◽  
Arterial Hypertension ◽  
Enzyme Inhibitors ◽  
Enzyme Inhibitor ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors

The paper focuses on the justification for preferential administration of antihypertensive combination therapy. Pharmacotherapeutic features of starting the treatment with a combination of angiotensin-converting enzyme inhibitors (ACEI) and calcium antagonists (AC) are reviewed. The authors also present the latest evidence on the ACEI/AC combination effects on such vascular parameters as microcirculation and endothelial dysfunction.

Sign in / Sign up

Export Citation Format

Share Document